Source: ALL
Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD 		0.040 AlteredExpression disease BEFREE Phosphoinositide 3-kinase (PI3K) inhibitors have shown excellent activity in iNHL, specifically in MZL, with breakthrough designation status for copanlisib and umbralisib, allowing off label use of this class of agents in clinical practice. 31807935 2019
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD 		0.040 AlteredExpression disease BEFREE Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study. 30033575 2018
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD 		0.040 Biomarker disease BEFREE Duvelisib, an oral dual inhibitor of PI3K-δ and PI3K-γ, is in phase III trials for the treatment of chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin's lymphoma. 28017967 2017
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD 		0.040 Biomarker disease BEFREE Expert Opinion: PI3K inhibitors, particularly those that target p110δ, have robust efficacy in the treatment of CLL and iNHL. 28945111 2017
Entrez Id: 5294
Gene Symbol: PIK3CG
PIK3CG 		0.030 AlteredExpression disease BEFREE Phosphoinositide 3-kinase (PI3K) inhibitors have shown excellent activity in iNHL, specifically in MZL, with breakthrough designation status for copanlisib and umbralisib, allowing off label use of this class of agents in clinical practice. 31807935 2019
Entrez Id: 5294
Gene Symbol: PIK3CG
PIK3CG 		0.030 Biomarker disease BEFREE Expert Opinion: PI3K inhibitors, particularly those that target p110δ, have robust efficacy in the treatment of CLL and iNHL. 28945111 2017
Entrez Id: 5294
Gene Symbol: PIK3CG
PIK3CG 		0.030 Biomarker disease BEFREE Duvelisib, an oral dual inhibitor of PI3K-δ and PI3K-γ, is in phase III trials for the treatment of chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin's lymphoma. 28017967 2017
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA 		0.020 AlteredExpression disease BEFREE Phosphoinositide 3-kinase (PI3K) inhibitors have shown excellent activity in iNHL, specifically in MZL, with breakthrough designation status for copanlisib and umbralisib, allowing off label use of this class of agents in clinical practice. 31807935 2019
Entrez Id: 5291
Gene Symbol: PIK3CB
PIK3CB 		0.020 AlteredExpression disease BEFREE Phosphoinositide 3-kinase (PI3K) inhibitors have shown excellent activity in iNHL, specifically in MZL, with breakthrough designation status for copanlisib and umbralisib, allowing off label use of this class of agents in clinical practice. 31807935 2019
Entrez Id: 931
Gene Symbol: MS4A1
MS4A1 		0.020 Biomarker disease BEFREE Eligible patients included adults with biopsy-proven CD20-positive MCL and iNHL who met the criteria for treatment. 29056470 2018
Entrez Id: 54474
Gene Symbol: KRT20
KRT20 		0.020 Biomarker disease BEFREE Eligible patients included adults with biopsy-proven CD20-positive MCL and iNHL who met the criteria for treatment. 29056470 2018
Entrez Id: 5291
Gene Symbol: PIK3CB
PIK3CB 		0.020 Biomarker disease BEFREE Expert Opinion: PI3K inhibitors, particularly those that target p110δ, have robust efficacy in the treatment of CLL and iNHL. 28945111 2017
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA 		0.020 Biomarker disease BEFREE Expert Opinion: PI3K inhibitors, particularly those that target p110δ, have robust efficacy in the treatment of CLL and iNHL. 28945111 2017
Entrez Id: 54474
Gene Symbol: KRT20
KRT20 		0.020 GeneticVariation disease BEFREE Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. 18509084 2008
Entrez Id: 931
Gene Symbol: MS4A1
MS4A1 		0.020 GeneticVariation disease BEFREE Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. 18509084 2008
Entrez Id: 3558
Gene Symbol: IL2
IL2 		0.010 Biomarker disease BEFREE A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma. 17145827 2006
Entrez Id: 5243
Gene Symbol: ABCB1
ABCB1 		0.010 AlteredExpression disease BEFREE MDR1 RNA levels were occasionally elevated in other untreated cancers, including neuroblastoma, acute lymphocytic leukemia (ALL) in adults, acute nonlymphocytic leukemia (ANLL) in adults, and indolent non-Hodgkin's lymphoma. 2562856 1989
Entrez Id: 23158
Gene Symbol: TBC1D9
TBC1D9 		0.010 AlteredExpression disease BEFREE MDR1 RNA levels were occasionally elevated in other untreated cancers, including neuroblastoma, acute lymphocytic leukemia (ALL) in adults, acute nonlymphocytic leukemia (ANLL) in adults, and indolent non-Hodgkin's lymphoma. 2562856 1989